

## II. REMARKS

### **Restriction Requirement**

Claims 1-28 were pending. The Examiner has required restriction of the claims to one of eight groups under 35 U.S.C. §121.

Applicants elect without traverse to prosecute the invention of the Group 1 claims drawn to an antibody mutant wherein the non-human primate in claim 5 is rhesus.

### **Amendments to the claims**

As a result of the restriction requirement, claims 14-28 are withdrawn. By virtue of this amendment, claims 6, 7, 11-13 are canceled without prejudice to refiling continuing application(s) directed thereto. Claims 1, 2, 8 and 9 are amended and claims 29-30 are added. Upon entry of this amendment, claims 1-5, 8-10 and 29-30 will be pending.

The amendments in claim 1 are supported by claim 13, page 4, line 20-22, and page 24, lines 15-17 in the specification. Dependent claims 2, 8, 9 are amended to recite "CD11a" as in amended claim 1, instead of antigen. New claim 29 finds support on page 4 at lines 20-22 of the specification. New claim 30 finds support in the specification, for example, on page 40, lines 14-16.

No new matter has been introduced by these amendments and their entry is respectfully requested. Reconsideration of the claims, as amended, are respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-0630 (Ref. Docket No. P1064R1C1).

Respectfully submitted,  
GENENTECH, INC.

Date: March 31, 2005

By: Lee K. Tan  
Lee K. Tan, Ph.D.  
Reg. No. 39,447  
Telephone: (650)225-4462